Daniel O’Day is getting about $30 million in cash and stock to save the stagnant Gilead Sciences (GILD). On Thursday, investors get their first chance to decide whether he’s worth the money.

O’Day, who started as Gilead CEO in March, will host his first quarterly earnings call after the market closes, giving the Roche (RHHBY) veteran a chance to explain his vision for the company, weigh in on some recent setbacks, and get some practice answering the question he’ll face every three months from now on: What are you going to buy?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy